Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.40 |
| ▸ | BRAF | P15056 | 13/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | KIF5B | P33176 | 2/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427820 | 0.81 | KDR (0.55) | KDRRETKIF5BRAF1 | |
| SCHEMBL4693982 | 0.81 | EPHB4 (0.45) | KDREPHA2RETKIF5BEPHB4 | |
| SCHEMBL4693096 | 0.80 | KIT (0.50) | KDREPHA2RETKIF5BEPHB4 | |
| SCHEMBL4686367 | 0.77 | EGFR (0.55) | KDRRETKIF5B | |
| SCHEMBL4689472 | 0.73 | EPHB4 (0.43) | KDREPHA2EPHB4ERBB2 | |
| SCHEMBL4689382 | 0.73 | EGFR (0.58) | KDRRETKIF5BRAF1 | |
| SCHEMBL4689354 | 0.73 | KDR (0.58) | KDREPHA2RETKIF5BEPHB4 | |
| SCHEMBL4690072 | 0.73 | EGFR (0.54) | KDRRETKIF5B | |
| SCHEMBL4690835 | 0.69 | EGFR (0.56) | KDREPHA2RETKIF5BEPHB4 | |
| SCHEMBL4690287 | 0.68 | EGFR (0.56) | KDREPHA2RETKIF5BEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296973-B1 | GUANIDINE DERIVATIVES OF QUINAZOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-7001904-B1 | Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | disclosed |
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |